AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Atomoxetine: serious liver injury.(Safety and Efficacy Issues)
United States of America -- The Food and Drug Administration (FDA) continues to receive reports of serious liver injury in patients given atomoxetine. Atomoxetine received FDA approval on 26 November 2002 as the first non-stimulant medication used for the treatment of attention deficit hyperactivity disorder (ADHD) in children (aged 6 years and above) and adults (1).
Atomoxetine's therapeutic action is believed to be due to its selective inhibition of norepinephrine reuptake. From the year 2002 to 2007, approximately 3.3 million patients received a prescription for atomoxetine in the United States. Of those, approximately 2.1 million patients (64%) were children aged 17 years …
-
- Severe liver injury with atomoxetine.(CASE REPORT)(Brief Article)
-
Newspaper article from: The Brown University Child and Adolescent Psychopharmacology Update
December 1, 2005
700+ words
-
- Atomoxetine Hydrochloride
-
Newspaper article from: The Brown University Child and Adolescent Psychopharmacology Update
November 1, 2012
700+ words
-
- Atomoxetine hydrochloride (brand: Strattera).
-
Newspaper article from: The Brown University Child and Adolescent Psychopharmacology Update
September 1, 2010
700+ words
-
- Atomoxetine hydrochloride.(PATIENT INFORMATION SHEET)(Drug overview)
-
Newspaper article from: The Brown University Child and Adolescent Psychopharmacology Update
February 1, 2009
700+ words
-
- Atomoxetine hydrochloride: brand: strattera.(PATIENT INFORMATION SHEET)(Drug...
-
Newspaper article from: The Brown University Child and Adolescent Psychopharmacology Update
January 1, 2009
700+ words
